Histopathological Findings in Brain Tissue Obtained during Epilepsy Surgery
DOI: https://doi.org/10.1056/NEJMoa1703784
2019-10-03
Abstract:Background Detailed neuropathological information on the structural brain lesions underlying seizures is valuable for understanding drug-resistant focal epilepsy. Methods We report the diagnoses made on the basis of resected brain specimens from 9523 patients who underwent epilepsy surgery for drug-resistant seizures in 36 centers from 12 European countries over 25 years. Histopathological diagnoses were determined through examination of the specimens in local hospitals (41%) or at the German Neuropathology Reference Center for Epilepsy Surgery (59%). Results The onset of seizures occurred before 18 years of age in 75.9% of patients overall, and 72.5% of the patients underwent surgery as adults. The mean duration of epilepsy before surgical resection was 20.1 years among adults and 5.3 years among children. The temporal lobe was involved in 71.9% of operations. There were 36 histopathological diagnoses in seven major disease categories. The most common categories were hippocampal sclerosis, found in 36.4% of the patients (88.7% of cases were in adults), tumors (mainly ganglioglioma) in 23.6%, and malformations of cortical development in 19.8% (focal cortical dysplasia was the most common type, 52.7% of cases of which were in children). No histopathological diagnosis could be established for 7.7% of the patients. Conclusions In patients with drug-resistant focal epilepsy requiring surgery, hippocampal sclerosis was the most common histopathological diagnosis among adults, and focal cortical dysplasia was the most common diagnosis among children. Tumors were the second most common lesion in both groups. (Funded by the European Union and others.) Supported by the European Union (FP7 DESIRE GA grant 602531, to Drs. Blumcke, Spreafico, Haaker, Tassi, Guerrini, and Barba; FP7 EPITARGET GA grant 602102, to Drs. Becker, Aronica, Walker, and Sisodiya; FP7 EPISTOP grant 602391, to Dr. Aronica; and FP7 EpimiRNA GA grant 602130, to Drs. Hamer and Rosenow); EpiGENet (DFG Bl 421/3-1, to Dr. Blumcke); the Johannes and Frieda Marohn Foundation of the Friedrich-Alexander University Erlangen-Nuremberg (support to Dr. Blumcke); the Austrian Science Fund (FWF grant J3499, to Dr. Mühlebner and grants P21636, P24367, DK W 1233-G17, KLI543-B27, and KLI12-B00, to Dr. Trinka); the Italian Ministry of Health (grant RF-2011-02350578, to Drs. Spreafico, Tassi, and Guerrini, and grant RF-2010-2309954, to Dr. Barba), the National Institute for Health Research University College London Hospitals Biomedical Research Centre (support to Drs. Thom, Walker, Sisodiya, Duncan, and McEvoy); Great Ormond Street Hospital Children’s Charity, the Brain Tumour Charity, Children with Cancer, Higher Education Funding Council for England, and the National Institute for Health Research (support to Dr. Jacques); the Anniversary Fund of the Central Bank of the Republic of Austria (grant ÖNB-12036, to Dr. Feucht); and Fundación Gmp (support to Dr. Gil-Nagel). Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. Dr. Kobow reports receiving lecture fees from Nutricia; Dr. Bien, receiving lecture fees, consulting fees, and travel support from Eisai, UCB, and Desitin, grant support and travel support from Griflos, grant support and lecture fees from Diamed and Fresenius Medical Care, lecture fees from Euroimmun, and consulting fees from Laboratory Krone; Dr. Elger, receiving honoraria and consulting fees from UCB, Desitin, Bial, and Eisai; Dr. Hamer, receiving advisory board fees and lecture fees from UCB, Desitin, Eisai, and Novartis, advisory board fees from Cerbomed, and lecture fees from Hexal and Boehringer Ingelheim; Dr. Stefan, receiving honoraria from Eisai, Elekta, Novartis, LivaNova, and Desitin; Dr. Walker, receiving grant support from Vitaflo, lecture fees and advisory board fees from Eisai and UCB Pharma, consulting fees from GlaxoSmithKline and Pfizer, lecture fees from Special Products, advisory board fees from Sanofi, holding a patent on “Therapeutic use of compounds” (WO 2012069790) licensed to Vitaflo, and holding a patent on “Combined use of a vector encoding a modified receptor and its exogenous agonist in the treatment of seizures” (WO 2015136247); Dr. Duncan, receiving grant support from Wellcome Trust; Dr. Schulze-Bonhage, receiving grant support from Bial -Abstract Truncated-